IL33 and lung carcinoma: In this study, we demonstrated that both CAFs and tumor cells treated with DNA damage-inducing agents secrete high levels of IL-33, which promotes DDR and chemoresistance in lung cancer cells (Supplementary Fig. S5B, S5C and Fig. 4C).